Sara Di Lorenzo

Dr. Sara Di Lorenzo

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 September 2022 in Nutrients
Verified
Journal Article
Open access
PDF file
RMRaffaella Memmola
Raffaella Memmola
APAngelica Petrillo
Angelica Petrillo
SLSara Di Lorenzo
Sara Di Lorenzo
SASara C. Altuna
Sara C. Altuna
Baker HabeebBaker Habeeb
Baker Habeeb
Michele GhidiniMichele Ghidini
Michele Ghidini
Extra virgin olive oil (EVOO) is a mainstay of the Mediterranean diet with its excellent balance of fats and antioxidant bioactive compounds. Both the phenolic and lipid fractions of EVOO contain a variety of antioxidant and anticancer substances which might protect from the development of colorectal cancer (CRC). The function of the intestinal microbiome is essential for the integrity of the intestinal epithelium, being protective against pathogens and maintaining immunity. Indeed, dysbiosis of the microbiota alters the physiological functions of the organ, leading to the onset of different diseases including CRC. It is known that some factors, including diet, could deeply influence and modulate the colon microenvironment. Although coming from animal models, there is increasing evidence that a diet rich in EVOO is linked to a significant reduction in the diversity of gut microbiome (GM), causing a switch from predominant bacteria to a more protective group of bacteria. The potential beneficial effect of the EVOO compounds in the carcinogenesis of CRC is only partially known and further trials are needed in order to clarify this issue. With this narrative review, we aim at discussing the available evidence on the effect of olive oil consumption on GM in the prevention of CRC.

12 June 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
SLSara Di Lorenzo
Sara Di Lorenzo
SFStefano Farese
Stefano Farese
CBCiro Balbo
Ciro Balbo
FMFederica Melisi
Federica Melisi
MSMarianna Scrima
Marianna Scrima
MFMorena Fasano
Morena Fasano
Extracranial metastases from meningioma are extremely rare with an incidence of <1% and their prognosis is poor. Moreover, there is currently no gold standard for their treatment and, therefore, the decision making is strictly depending upon multidisciplinary discussion. In this re-port, we describe the case of a 73-year-old patient who was diagnosed with a solitary lung metas-tasis over 20 years after initial treatment for a low-grade meningioma. Molecular characterization of this metastasis was performed by Oncomine Comprehensive Assay Plus recording multiple func-tional mutations on b2microglobulin and ATM genes. A short overview of the literature is also reported. To our knowledge, no previous reports exist on single pulmonary metastasis from low-grade meningioma occurring more than 20 years after diagnosis.

Verified
Journal Article
Open access
PDF file
SLSara Di Lorenzo
Sara Di Lorenzo
SFStefano Farese
Stefano Farese
CBCiro Balbo
Ciro Balbo
FMFederica Melisi
Federica Melisi
MSMarianna Scrima
Marianna Scrima
MFMorena Fasano
Morena Fasano
Extracranial metastases from meningiomas are extremely rare, with an incidence of <1%, and their prognosis is poor. Moreover, there is currently no gold standard for their treatment; therefore, the decision-making process is strictly dependent on multidisciplinary discussions. In this report, we describe the case of a 73-year-old patient who was diagnosed with a solitary lung metastasis more than 20 years after the initial treatment for a low-grade meningioma. Molecular characterization of this metastasis was performed using the Oncomine Comprehensive Assay Plus, which identified multiple functional mutations in the beta2-microglobulin (β2M) and ATM genes, both of which may contribute to immune evasion and genomic instability. A short overview of the literature is also reported. To our knowledge, no previous reports exist on single pulmonary metastasis from low-grade meningioma occurring more than 20 years after diagnosis.

30 July 2026 in Current Oncology
Verified
Journal Article
Open access
PDF file
GLGiuseppe Di Lorenzo
Giuseppe Di Lorenzo
SLSara Di Lorenzo
Sara Di Lorenzo
AVAntonio Verde
Antonio Verde
OSOriana Strianese Strianese
Oriana Strianese Strianese
LLLuigi Leo
Luigi Leo
CBCarlo Buonerba
Carlo Buonerba
Background: Next-generation sequencing (NGS)-detected ERBB2 amplification occurs in a subset of urothelial carcinomas, but its role as a treatment-selection marker for trastuzumab deruxtecan (T-DXd) remains uncertain. Methods: We retrospectively reviewed four patients with metastatic urothelial carcinoma treated with T-DXd in routine practice from 2024. Treatment selection was based on NGS-detected ERBB2 amplification because HER2 immunohistochemistry and in situ hybridization were unavailable. Results: Four men aged 65–76 years received T-DXd: one in the second line and three in the fourth or fifth line. The best radiological responses, abstracted from contemporaneous radiology reports and oncology medical records, were complete response in one patient, partial response in one, and stable disease in two. Three patients had previously received enfortumab vedotin. Documented adverse events included fatigue, anemia, diarrhea, rash, and leukopenia. No interstitial lung disease or pneumonitis was documented in the available records. Conclusions: These observations are descriptive and hypothesis-generating. They do not establish the efficacy or safety of T-DXd or validate ERBB2 amplification as a predictive biomarker, but they support prospective evaluation of genomic ERBB2 amplification when standard HER2 testing is unavailable.